Skip to main content

Antibodies Blocking Alpha-synuclein Toxicity and Spread for the Treatment of Parkinson’s Disease

Study Rationale:
Two main hallmarks of Parkinson’s disease (PD) are neurodegeneration and Lewy bodies, protein clumps comprising mainly of the protein alpha-synuclein. In diseases such as Parkinson’s, toxic alpha-synuclein clumps spread throughout the brain, damaging brain cells and causing neurodegeneration.

We hypothesize that stopping alpha-synuclein clumps from spreading or destroying them can prevent or stop neurodegeneration.

Study Design:
In this study, we will use a viral vector, a research tool that makes cells produce miniature proteins called antibodies. These proteins can stick to alpha-synuclein clumps and destroy them. Our viral vector will be injected into the spinal canal inside the spinal cord, where the mini-antibodies will begin their spread throughout the brain. We expect our approach to block toxic effects of alpha-synuclein and prevent neurodegeneration and resulting motor symptoms of PD.

Impact on Diagnosis/Treatment of Parkinson’s Disease:
This study will reveal the ability of our therapeutic approach to stop the progression of Parkinson’s in pre-clinical models.

Next Steps for Development:
If successful, our approach could be optimized and tested in clinical trials and potentially become a new treatment for Parkinson’s disease.


  • Martin Lévesque, PhD

    Quebec City Canada

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.